TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a…
TORONTO, ON / ACCESSWIRE / September 27, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical…
The engagement is an additional step in the Company's path towards marketing clearance with the FDABRAINTREE, Mass., Sept. 27, 2023…
$3 million awarded by DoD to University of North Carolina Institute of Trauma Recovery to support a proposed 180-patient, randomized,…
Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023…
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be…
Prestigious Hacettepe University Hospital Expands Radiation Oncology Department to Offer the Latest Robotic Advance in Brain Tumor TreatmentsSAN CARLOS, Calif.--(BUSINESS…
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as…
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed…
STOCKHOLM, SE / ACCESSWIRE / September 26, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…